WALTHAM, Mass.–(BUSINESS WIRE)–December 21, 2016–
Augmenix, Inc. a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that separate and protect organs at risk during prostate radiotherapy, today announced that it will participate in the 35th Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco. John Pedersen, Chief Executive Officer, is scheduled to present on Thursday, January 12, 2017 at 9:30 a.m. Pacific Time in the Elizabethan D room.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161221005471/en/
About Augmenix, Inc.
Augmenix, Inc. is a privately held company based in the Boston area focused on the development and commercialization of radiation oncology products using its proprietary hydrogel technology. The company was founded by Incept LLC in 2008 and is funded by several leading venture capital groups. More information about Augmenix can be found at http://www.Augmenix.com.
Eileen Gardner, RN, 781-902-1625